| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b93cf25aebb1551539d3b1dc2636b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fd1de475659cdc01fa8d1d7b9c8596b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9a53e6ac3c6802f03783abb3cc121a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8778713427f3c00296d87dcb061a063e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaed355980118a6f393bc525c37a97d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a35c4ffd71b1f4a720642415c9178e47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b5d5ee831a6e2d5641fe4339bfcd29c |
| publicationDate |
2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8512701-B2 |
| titleOfInvention |
Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| abstract |
Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108289966-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017053170-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11219694-B2 |
| priorityDate |
2002-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |